Jan J. Jobsen - Concepedia

Author

Jan J. Jobsen

Also Known As

I. M. Jürgenliemk-Schulz, J J Jobsen, J Jobsen, J. J. Jobsen, J. Jobsen, J.J Jobsen, J.J. Jobsen, Jan J Jobsen, Jan J. Jobsen, Jan Jobsen

177

Publications

10.4K

Citations

H-Index

Concepts

All Affiliations

Medisch Spectrum Twente Leiden University Medical Center University Medical Center Utrecht Radboud University Nijmegen Maastro Clinic

About

Jan J. Jobsen is an author at Medisch Spectrum Twente specializing in oncology, medicine, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	30	46	6.5K
2	Health Sciences	11	11	935
3	Nursing	3	3	86
4	Public Health	2	2	120
5	Language Studies	1	1	24

Jan J. Jobsen

Publications

9.6K

Citations

H-Index

Page 1

	Year	Citations
Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial Carien L. Creutzberg, W L van Putten, P. Koper, The Lancet Gynecologic SurgerySurgical OncologyGynecological SurgeryRadiation TherapyMedicine	2000	1.7K
Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer—Combined Analysis of the PORTEC Cohorts Ellen Stelloo, Remi A. Nout, Elisabeth M. Osse, Clinical Cancer Research	2016	819
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial Stephanie M. de Boer, Melanie Powell, Linda Mileshkin, The Lancet Oncology	2018	599
Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: An European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874) Nicholas Reed, Costantino Mangioni, Henric Malmström, European Journal of Cancer European OrganisationRadiation TherapyMedicinePhase IiiGynecology	2008	520
10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study Marissa C. van Maaren, Linda de Munck, Geertruida H. de Bock, The Lancet Oncology Surgical OncologyBreast OncologyRadiation TherapyEarly Breast CancerMedicine	2016	427
Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer – A pooled analysis of PORTEC 1 and 2 trials Tjalling Bosse, Elke E.M. Peters, Carien L. Creutzberg, European Journal of Cancer A Pooled AnalysisPortec 1Gynecological SurgeryMedicineCancer Management	2015	407
Survival after relapse in patients with endometrial cancer: results from a randomized trial☆ Carien L. Creutzberg, Wim L.J. van Putten, P. Koper, Gynecologic Oncology Gynecological SurgeryMedicineCancer RecurrenceCancer ManagementGynecology	2003	367
Fifteen-Year Radiotherapy Outcomes of the Randomized PORTEC-1 Trial for Endometrial Carcinoma Carien L. Creutzberg, Remi A. Nout, Marnix L.M. Lybeert, International Journal of Radiation OncologyBiologyPhysics Radiation TherapyMedicineRandomized Portec-1 TrialGynecologyEndometrial Carcinoma	2011	357
Quality of Life After Pelvic Radiotherapy or Vaginal Brachytherapy for Endometrial Cancer: First Results of the Randomized PORTEC-2 Trial Remi A. Nout, Hein Putter, Ina M. Jürgenliemk‐Schulz, Journal of Clinical Oncology Quality Of LifeSurgical OncologyRadiation TherapyMedicineCancer Management	2009	269
Postoperative radiotherapy for Stage 1 endometrial carcinoma: Long-term outcome of the randomized PORTEC trial with central pathology review Astrid N. Scholten, Wim L.J. van Putten, H Beerman, International Journal of Radiation OncologyBiologyPhysics Gynecological SurgeryRadiation TherapyMedicineGynecologyStage 1	2005	241

Page 1